BrieMika NoelChunMD
Internal Medicine • Portland, ORHematology/Oncology
Hematology & Oncology fellow at Oregon Health & Science University
Dr. Chun is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Oregon Health & Science University
Portland, OR 97239
Summary
- Fellow in Hematology & Oncology at Oregon Health & Science University. Interested in immunotherapies, early-phase clinical trials, and breast cancer.
Education & Training
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2022 - 2025
Providence Health & Services - Oregon/St Vincent Hospital and Medical CenterResidency, Internal Medicine, 2017
University of Virginia School of MedicineClass of 2017
Certifications & Licensure
OR State Medical License 2020 - 2025- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 6 citationsReal-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer.Malinda T West, Malinda T West, Shaun M Goodyear, Evthokia A Hobbs, Andy Kaempf
The Oncologist. 2023-08-03 - 30 citationsMultiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.Katherine Sanchez, Isaac Kim, Brie Chun, Joanna Pucilowska, William L. Redmond
Breast Cancer Research. 2021-01-07 - 16 citationsA Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy.Isaac Kim, Venkatesh Rajamanickam, Brady Bernard, Brie Chun, Yaping Wu
Frontiers in Oncology. 2021-01-01
Journal Articles
- Combination Immunotherapy strategies in breast cancerChun B, Page DB, McArthur HL, Current Breast Cancer Reports, 12/2019
Abstracts/Posters
- A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metast...Page DB, Kim IK, Chun B, Redmond WL, Martel M, Mori M, Wadell D, Moxon N, Mellinger SL, Urba WJ, Gucalp A, Traina TA, ASCO, Chicago IL, 5/2019
- First or second line pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC)Page DB, Chun B, Pucilowska J, Kim I, Sanchez K, Redmond WL, Sun Z, Wu Y, Feryn A, Martel M, Abaya CD, Wadell D, Mellinger S, Moxon N, Urba WJ, McAndrew P, El-Masry M,..., ASCO, Chicago, IL, 5/2019
Professional Memberships
- Member
- Member
- Society for Immunotherapy of CancerMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
